Parabilis Medicines, Inc. (PBLS) Diversifiers

Equity · Currency in USD · Last updated Jul 25, 2026

Parabilis Medicines, Inc. is a clinical-stage biopharmaceutical company developing stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, led by FOG-001, a TCF-blocking beta-catenin inhibitor for cancer treatment. The company was formerly known as FogPharma, was founded in 2015, and is based in Cambridge, Massachusetts. It completed its initial public offering on the Nasdaq Global Select Market in June 2026.

Looking to balance out your exposure to PBLS? The ETFs below have the lowest correlation with PBLS — they tend to move on their own, which can help reduce risk when PBLS drops. The stock ideas table highlights individual companies that behave independently from PBLS.

No Diversifiers Found for PBLS

We do not have enough correlation history to rank diversifiers for this symbol yet.

Diversification Analysis

Build a portfolio that complements PBLS

Add PBLS to the Diversification Analyzer to see how it overlaps with your other holdings and which assets balance it best.

Analyze a portfolio with PBLS